AR076984A1 - Derivados de pirazol oxadiazol - Google Patents
Derivados de pirazol oxadiazolInfo
- Publication number
- AR076984A1 AR076984A1 ARP100101985A ARP100101985A AR076984A1 AR 076984 A1 AR076984 A1 AR 076984A1 AR P100101985 A ARP100101985 A AR P100101985A AR P100101985 A ARP100101985 A AR P100101985A AR 076984 A1 AR076984 A1 AR 076984A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- indicates
- het1
- cor4
- carbon atoms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
La presente se refiere a derivados de pirazol oxadiazolos de la Formula (1), y al uso de los mismos para tratar esclerosis multiple y otras enfermedades. Reivindicacion 1: Compuestos de la formula (1): en donde R1 indica Ar1, Het1, Cyc, A, (C1-6)alquilo, (C2-6)alquilo, -(CH2)nAr1, (CH2)nHet1, (CH2)nHet2; R2 es Ar2, Het1; R3 indica Ar1, Ar2, Het1, Het2, Cyc o A, o si R1 es Het1, Cyc, A, -(CH2)nAr1, (CH2)nHet1, (CH2)nHet2, (C2-6)alquilo, o si R1 indica Ar1 o R2 es Ar2, Het1 o Het2 en donde Ar1 y Ar2 son mono, di o trisustituidos por los sustituyentes mencionados en la presente, R3 también indica CH3 o si R1 indica Het1, Cyc, A, (C1-6)alquilo, (C2-6)alquilo, -(CH2)nAr1, (CH2)nHet1, (CH2)nHet1, R3 también indica S-(C1-6-alquil), A es un alquilo ramificado o lineal que posee 2 a 12 átomos de carbono, en donde uno o más, preferentemente 1 a 7 átomos H pueden reemplazarse por Hal, OR4, CN, CO2R4, CF3, cicloalquilo con 3 a 7 átomos de carbono de anillo, Ar1, Ar2, o N(R4)2 y en donde uno o más, preferentemente 1 a 7 grupos CH2- no adyacentes pueden reemplazarse por O, NR4, -CO-, NR4CO2-, -CO2-, -NR4CONR4-, -CH=CH-, -C:::C-, o indica cicloalquilo o cicloalquilalquileno con 3-7 átomos de carbono de anillo, o indica Het1 o Het2; Z es un alquilo ramificado o lineal que posee 2 a 12 átomos de carbono, en donde uno o más, preferentemente 1 a 7 átomos H son reemplazados por Hal, OR4, CN, CO2R4, CF3, cicloalquilo con 3 a 7 átomos de carbono de anillo, Ar1, Ar2, N(R4)2 y/o en donde uno o más, preferentemente 1 a 7 grupos CH2- son reemplazados por O, NR4, S, -CO-, NR4CO2-, -NR4CONR4-, -CH=CH-, -C:::C-, o indica cicloalquilo o cicloalquilalquileno con 3-7 átomos de carbono de anillo; Hal es F, Cl, Br o I; Ar1 indica un anillo carbocíclico monocíclico o bicíclico, insaturado o aromático con 6 a 14 átomos de carbono que puede ser insustituido, monosustituido, disustituido o trisustituido por sustituyentes seleccionados entre A, Hal, -OR4, -SO2R4, -CN, -NO2, -N(R3)2, -CO(NR4)2, -OR4, (NR4)COR4, -CO2R4, -COR4, -SO2N(R4)2, -SO2alquilo, NR4SO2alquilo, NR4SO2alquilo, o C1-6 alquilo; Ar2 indica un anillo carbocíclico monocíclico o bicíclico, insaturado o aromático con 6 a 14 átomos de carbono que puede ser insustituido, monosustituido, disustituido o trisustituido por sustituyentes seleccionados entre Z, F, Br, I, -OR4, -(CH2)OR4, -(CH2)N(R4)2, Perfluoro-alcoxi, -SO2R4, -CN, -NO2, - N(R4)2, -CO(NR4)2, (NR4)COR4, -CO2R4, -COR4, -SO2N(R4)2, -SO2 (C1-6)alquilo, NR4SO2(C1-6)alquilo, -(CH2)nHet1, -OHet1, -(CH2)nHet2, -OHet2, o si R3 es Het1, Het2, Ar1, Ar2 o Cyc, o si R1 es Het1, Cyc, A, (C1-6)alquilo, (C2-6)alquilo, -(CH2)nAr1, (CH2)nHet1, (CH2)nHet1, Ar2 también indica un anillo carbocíclico monocíclico o bicíclico, insaturado o aromático con 6 a 14 átomos de carbono que puede ser insustituido, monosustituido, disustituido o trisustituido por CF3. Het1 indica un anillo monocíclico saturado, insaturado o heterocíclico aromático o un anillo bicíclico, saturado o heterocíclico insaturado que posee 1 a 4 átomos N y/o O que puede ser insustituido, monosustituido, disustituido o trisustituido por sustituyentes seleccionados entre A, Hal, -OR4, -(CH2)OR4, Perfluoro-alquilo, Perfluoro-alcoxi, -SO2(R4)2, CN, NO2, -N(R4)2, -CO(NR4)2, (NR4)COR4, -CO2R4, -COR4, -SO2N(R4)2, -SO2alquilo, NR4SO2alquilo, NR4SO2alquilo, o C1-6 alquilo. Het2 indica un anillo monocíclico o bicíclico saturado, insaturado o heterocíclico aromático con 1 a 4 átomos N, O y/o S que puede ser insustituido, moriosustituido, disustituido o trisustituido por sustituyentes seleccionados entre A, F, Br, I, -OR4, -(CH2)OR4, Perfluoro-alquilo, Perfluoro-alcoxi, -SO2(R4)2, CN, NO2, -N(R4)2, -CO(NR4)2, (NR4)COR4, -CO2R4, -COR4, -SO2N(R4)2, -SO2alquilo, NR4SO2alquilo, NR4SO2alquilo, o C1-6 alquilo; Cyc indica un anillo carbocíclico saturado o insaturado que contiene 3 a 7 átomos de carbono que puede ser sustituido por Hal, A, (C1-6)alquilo, -[C(R4)2]n-Ar, -[C(R4)2]n-cicloalquilo, OR4, CF3, OCF3, N(R4)2, NR4CON(R4)2, NO2, CN, -[C(R4)2]n-COOR4, -[C(R4)2]n-CON(R4)2, NR4COA, NR4SO2A, COR4, CO2R4, SO2N(R4)2, SOA, y/o SO2A. R4 es H, A, Cyc o (C1-6)alquilo, preferentemente H o (C1-6)alquilo; n es 1, 2, 3 o 4 y derivados farmacéuticamente aceptables, solvatos, tautomeros, sales y estereo-isomeros de los mismos, incluyendo mezclas de los mismos en todas las proporciones como un medicamento, especialmente para tratar esclerosis multiple y otras enfermedades.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09162206 | 2009-06-08 | ||
US21847709P | 2009-06-19 | 2009-06-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076984A1 true AR076984A1 (es) | 2011-07-20 |
Family
ID=40839662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101985A AR076984A1 (es) | 2009-06-08 | 2010-06-04 | Derivados de pirazol oxadiazol |
Country Status (9)
Country | Link |
---|---|
US (1) | US8802663B2 (es) |
EP (1) | EP2440554B1 (es) |
JP (1) | JP5837482B2 (es) |
AR (1) | AR076984A1 (es) |
AU (1) | AU2010257564B2 (es) |
CA (1) | CA2763683C (es) |
ES (1) | ES2638398T3 (es) |
IL (1) | IL216692A (es) |
WO (1) | WO2010142628A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2560969B1 (en) * | 2010-04-23 | 2015-08-12 | Bristol-Myers Squibb Company | 4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists |
US20130137865A1 (en) * | 2010-08-11 | 2013-05-30 | Taisho Pharmaceutical Co., Ltd. | Heteroaryl-pyrazole derivative |
JP5869579B2 (ja) | 2010-09-24 | 2016-02-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 置換オキサジアゾール化合物およびそれらのs1p1アゴニストとしての使用 |
JP2014062047A (ja) * | 2011-01-21 | 2014-04-10 | Taisho Pharmaceutical Co Ltd | ピラゾール誘導体 |
ES2664507T3 (es) * | 2011-01-28 | 2018-04-19 | Immunic Ag | Inhibición de IL17 e IFN-gamma para el tratamiento de una inflamación autoinmunitaria |
EP2738170B1 (en) | 2011-07-29 | 2017-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
JP2015078127A (ja) * | 2012-01-25 | 2015-04-23 | 大正製薬株式会社 | N−置換ピラゾール誘導体 |
UA114915C2 (uk) | 2012-07-02 | 2017-08-28 | Монсанто Текнолоджи Ллс | Спосіб одержання 3,5-дизаміщених 1,2,4-оксадіазолів (варіанти) |
RU2712192C2 (ru) * | 2014-07-31 | 2020-01-24 | Басф Се | Способ получения пиразолов |
KR102585412B1 (ko) | 2015-05-11 | 2023-10-05 | 바스프 에스이 | 4-아미노-피리다진의 제조 방법 |
RU2733958C2 (ru) | 2016-02-02 | 2020-10-08 | Басф Се | Способ каталитического гидрирования для получения пиразолов |
CN112552288A (zh) * | 2021-02-19 | 2021-03-26 | 南京桦冠生物技术有限公司 | 一种4-肟-5`-(2-甲基丙酰基)尿苷的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2795726A1 (fr) * | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
AU2003287965A1 (en) * | 2002-10-24 | 2004-05-13 | Carex Sa | Modulation of peroxisome proliferator activated receptors activity |
ES2887054T3 (es) | 2003-04-11 | 2021-12-21 | Ptc Therapeutics Inc | Compuesto de ácido 1,2,4-oxadiazol benzoico y su uso para la supresión sin sentido y el tratamiento de enfermedades |
JP2008545767A (ja) | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 多環式オキサジアゾールまたはイソキサゾールおよびsip受容体リガンドとしてのそれらの使用 |
WO2008076356A1 (en) * | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
GB0625648D0 (en) * | 2006-12-21 | 2007-01-31 | Glaxo Group Ltd | Compounds |
EP2176249A2 (en) | 2007-07-02 | 2010-04-21 | Boehringer Ingelheim International GmbH | New chemical compounds |
JP2012515789A (ja) * | 2009-01-23 | 2012-07-12 | ブリストル−マイヤーズ スクイブ カンパニー | スフィンゴシン−1−リン酸アゴニストとしてのピラゾール−1,2,4−オキサジアゾール誘導体 |
-
2010
- 2010-06-04 AR ARP100101985A patent/AR076984A1/es unknown
- 2010-06-07 EP EP10724789.2A patent/EP2440554B1/en active Active
- 2010-06-07 ES ES10724789.2T patent/ES2638398T3/es active Active
- 2010-06-07 WO PCT/EP2010/057893 patent/WO2010142628A1/en active Application Filing
- 2010-06-07 JP JP2012514435A patent/JP5837482B2/ja not_active Expired - Fee Related
- 2010-06-07 US US13/322,939 patent/US8802663B2/en not_active Expired - Fee Related
- 2010-06-07 AU AU2010257564A patent/AU2010257564B2/en not_active Ceased
- 2010-06-07 CA CA2763683A patent/CA2763683C/en not_active Expired - Fee Related
-
2011
- 2011-11-30 IL IL216692A patent/IL216692A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
US8802663B2 (en) | 2014-08-12 |
IL216692A0 (en) | 2012-02-29 |
EP2440554A1 (en) | 2012-04-18 |
US20120071460A1 (en) | 2012-03-22 |
ES2638398T3 (es) | 2017-10-20 |
IL216692A (en) | 2017-09-28 |
EP2440554B1 (en) | 2016-10-05 |
WO2010142628A1 (en) | 2010-12-16 |
JP5837482B2 (ja) | 2015-12-24 |
CA2763683C (en) | 2018-05-15 |
CA2763683A1 (en) | 2010-12-16 |
AU2010257564B2 (en) | 2016-09-29 |
AU2010257564A1 (en) | 2011-12-08 |
JP2012529459A (ja) | 2012-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076984A1 (es) | Derivados de pirazol oxadiazol | |
ES2445405T3 (es) | Derivados de la 6-amino-pirimidina-4-carboxamida y compuestos relacionados que se unen al receptor de la esfingosina 1-fosfato (s1p) para el tratamiento de la esclerosis múltiple | |
AR074622A1 (es) | Derivados de acido ciclopentanocarboxilico condensados sustituidos con acilamino y su uso como productos farmaceuticos | |
AR068730A1 (es) | Compuestos de diaril 1,2,4-oxadiazol,composiciones farmaceuticas que los contienen,proceso de preparacion y uso de los mismos como agentes inmunosupresores en el tratamiento de enfermedades autoinmunes y/o inflamatorias cronicas. | |
CO2017011038A2 (es) | Derivados de (s)-2-((2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)amino)amidas como inhibidores de pi3kca” | |
CO6210729A2 (es) | Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona procedimientos para su preparacion y su uso como agente farmaceutico | |
CO6620072A2 (es) | Compuestod de benzoxepina inhibidores de la pi3k y métodos de uso | |
AR068731A1 (es) | Compuestos de diaril 1,2,4-oxadiazol,composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes inmunosupresores en el tratamiento de enfermedades autoinmunes y/o inflamatorias cronicas. | |
PE20151375A1 (es) | Compuestos ciclicos eter pirazol-4-il-heterociclil-carboxamida y metodos de utilizacion | |
AR064155A1 (es) | Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso | |
AR067093A1 (es) | N-(2-(hetaril) arilsulfonamidas y n-(2-( heteraril) hetaril) arilsulfonamidas | |
ES2548998T3 (es) | Composiciones antifúngicas de azol | |
AR076187A1 (es) | Derivados de oxadiazol, proceso de preparacion de los mismos y composicion farmaceutica que los contienen | |
AR067562A1 (es) | Compuestos heterociclicos inhibidores de kinasa | |
UY31906A (es) | Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias. | |
AR071055A1 (es) | Compuestos espiro, composiciones farmaceuticas y medicamentos que los comprenden, agente promotor de la secrecion de insulina y usos para la preparacion de medicamentos y composiciones farmaceuticas | |
CR20160287A (es) | Inhibidores de syk | |
AR053569A1 (es) | Derivados de pirazol | |
CO6390026A2 (es) | Derivados de isoxazol para uso como reguladores del crecimiento de plantas | |
AR060632A1 (es) | Compuestos inhibidores de fosfoinositida 3- quinasa y metodos de uso | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
BR112014025564B8 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma | |
ES2589558T3 (es) | Derivados de pirimidin pirazolilo | |
AR075321A1 (es) | Compuestos de amidina sustituida para combatir plagas de animales | |
AR072792A1 (es) | DERIVADOS DE PIRROLOPIRIDINILPIRIMIDIN-2-IL-AMINA, PROCEDIMIENTO DE PREPARACIoN Y COMPOSICIONES FARMACEUTICAS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |